Skip to main
MIST

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals is a promising biopharmaceutical company with their recent launch of Cardamyst in the US. Along with potential for non-dilutive cash flow and growth, the drug has gained commercial coverage and is being promoted to physicians as a convenient and cost-effective option for treating PSVT and AFib-RVR. However, challenges in achieving desired prescription volume and revenue, as well as uncertainties surrounding the success of their Phase 3 trial for AFib-RVR treatment, make the company's future prospects less clear.

Bears say

Milestone Pharmaceuticals is facing several fundamental challenges, including limited insurance coverage and low investor valuation due to skepticism about the commercial potential of its lead product, Cardamyst. Additionally, the company is currently experiencing operating losses and may require additional capital in the future. Finally, the success of expanding Cardamyst into AFib-RVR treatment depends on the results of ongoing clinical trials and subsequent regulatory approvals, which are uncertain.

MIST has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 4 analysts, MIST has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.